Vyloy (Zolbetuximab-Clzb) | aBLA Filing Intelligence & Biosimilar Opportunity

Vyloy

Vyloy is used with fluoropyrimidine and platinum-based chemotherapy as the first-line treatment for HER2-negative gastric or gastroesophageal junction cancer, which cannot be removed by surgery or has spread and tests positive for claudin (CLDN)18.2.

The information outlined in the molecule details section below would help you plan aBLA development early to enable a streamlined and competitive biosimilar strategy.

Molecule Details :

Molecule Name :

Zolbetuximab-Clzb
Innovator :

ASTELLAS PHARMA US, INC.
Approval Date :

18-Oct-24
Data Exclusivity Expiry :

18-Oct-28
Market Exclusivity Expiry :

18-Oct-36
Dosage Form :

Intravenous Infusion
Strength :

100mg/vial
Therapeutic Category :

Anticancer
Revenue ($M) :

406

Year-wise Projected Sales ($M) :

2026 :

520
2027 :

676
2028 :

843
2029 :

981
2030 :

1099
2031 :

1218
2032 :

1335

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Vyloy

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?